Key facts
- Gut-Brain Axis Therapeutics’s last known valuation is $39.0M (Nov 2025).
- It has raised $3.4M across 2 recorded rounds; the latest was Seed Round ($2.0M) in Oct 2025.
- Notable investors include HealthTech Capital, Skysong Innovations.
- Gut-Brain Axis Therapeutics has filed 1 Form D with the SEC, most recently Oct 2023 ($1.4M sold to 23 investors).
- Status: Privately Held (backing).
Investors
2- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Gut-Brain Axis Therapeutics
Funding rounds
2 roundsAbout Gut-Brain Axis Therapeutics
Developer of the healthcare therapy intended to improve the gut microbiota and gut health. The company provides services in the development of new products with a particular focus on microbiota transplant therapy for autism and Pitt-Hopkins syndrome, enabling healthcare providers to improve brain and gut health.
- Sector
- Healthcare
- HQ
- Tempe, AZ, United States
- Founded
- 2022
- Ownership
- Privately Held (backing)
Gut-Brain Axis Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gut-Brain Axis Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gut-Brain Axis Therapeutics in its N-PORT filings yet. We sweep new filings monthly.